GLP-1, GIP, and glucagon each have their own receptor. Three hormones, three locks. So how does a single research-grade peptide — tirzepatide, for example, or retatrutide — bind and activate two or three of those receptors with one chemical structure? This article is a plain-language tour of multi-receptor agonist peptide design, the corner of peptide chemistry that builds one molecule to engage several receptors at researcher-tunable ratios. Everything below is framed for research use only; the compounds we name are tools studied in cell-culture and animal models, not consumer products. We'll cover three sub-questions: what "multi-receptor" actually means at the structural level, how laboratories engineer such peptides, and what trade-offs come with combining receptors in a single molecule.
One Peptide, More Than One Receptor — What Does That Mean?
Picture a receptor on the outside of a cell as a multi-chambered lock. A peptide that fits into it makes contact at several specific points along its chain. The receptor responds to those contacts by reshaping itself on the inside of the cell, which kicks off a signal. That's what researchers mean when they say a peptide "activates" a receptor.
Most native peptide hormones bind one main receptor. A multi-receptor agonist is a single engineered peptide whose sequence is built so that one chain fits — well enough to trigger activation — into more than one related receptor lock. One chemical compound, not a mixture. The same molecular chain enters all of its target receptors. Researchers tune which receptor the peptide prefers by choosing which residues sit at the surface-contact positions.
For broader context on how receptors are grouped into families and why some are evolutionary cousins, we've written a separate plain-language piece on the broader family of peptide receptors.
The Canonical Example — GLP-1, GIP, and Glucagon
Three members of the class B1 G-protein-coupled receptor family are the standard worked example: the GLP-1 receptor (GLP-1R), the GIP receptor (GIPR), and the glucagon receptor (GCGR). Each is the natural target of one peptide hormone — GLP-1, GIP, and glucagon respectively. The three hormones share enough sequence similarity that a chimeric peptide can mimic features of two or even all three at once. Three locks similar enough that a carefully cut key opens more than one.
Tirzepatide is the most-studied dual receptor agonist in this family. Researchers engineered it from the human GIP sequence, then substituted specific residues so the same peptide also engages GLP-1R. Binding studies put its affinity for GIPR at roughly the level of native GIP, with about an 18- to 20-fold lower affinity for GLP-1R — and that ratio is itself a design parameter, not an accident. We go deeper into the molecular detail in our companion piece on tirzepatide structure and dual GIP/GLP-1 receptor pharmacology. A 2022 paper in Nature Communications resolved the cryo-EM structures of tirzepatide bound to GIPR and GLP-1R and explained the residue-by-residue basis of that selectivity ratio (Zhao et al., 2022).
A naming note before we move on. "Tirzepatide" is a generic peptide name shared by an FDA-approved pharmaceutical product made by a regulated manufacturer. Research-grade tirzepatide reference material isn't equivalent to that pharmaceutical product, even though the chemical sequence is the same on paper. Different sourcing, different purity verification, different intended use. Optides supplies the former — for research use only.
Why Combine Receptors at All?
The plain answer: each receptor in this family contributes a different effect in cell-culture and animal models, and a single peptide that activates them in the right proportions integrates those effects in one binding event. GLP-1R activity is associated in research models with reduced food intake and improved insulin response; GIPR activity contributes complementary metabolic signaling; GCGR activity is associated with increases in energy expenditure observed in those same models. The combinatorial-hormone-therapy idea — laid out in the literature on next-generation triagonists — is that one molecule designed to engage all three at the right ratio gives researchers a single tool to study how those signals interact (Knerr et al., 2022).
There's a practical reason too. Three separate peptides means three separate half-lives, three separate clearance profiles, and three separate receptor-exposure curves that almost never align cleanly in the same animal model. A single molecule has one pharmacokinetic profile and one tuning knob: the researcher changes one sequence and re-runs the assays. Much cleaner experimentally than co-formulating three peptides whose blood-level curves never quite cooperate.
From Two Receptors to Three
Retatrutide (also called LY3437943) is the headline triple agonist. It binds and activates GLP-1R, GIPR, and GCGR — all three receptors of the family — with a researcher-tuned potency ratio. Compared to the corresponding native hormones, retatrutide is roughly 8.9-fold more potent at GIPR and roughly 0.3 to 0.4 times as potent at GCGR and GLP-1R (Li et al., Cell Discovery 2024). The take-home isn't the exact numbers; it's that the ratio between the three receptors was an intentional design output. Our companion article on retatrutide's triple agonism at GLP-1R, GIPR and GCGR walks through the per-receptor design choices.
What does the molecule actually look like inside each receptor? A 2024 cryo-electron microscopy study captured retatrutide bound to all three. Same peptide, same overall shape — a single continuous alpha-helix — in every receptor. Its N-terminal half (residues 1 through about 13) penetrates the conserved transmembrane core of each receptor; that part is the universal activation switch. Its C-terminal half (residues 14 through 30) wraps against the receptor's extracellular surface — the part that differs from one receptor to the next — and makes the receptor-specific contacts that decide how tightly the peptide binds. Superimpose the three retatrutide-bound receptor structures and the alpha-carbon root-mean-square deviation is only 0.88 to 0.93 angstroms. Activation chemistry, conserved across the family. Selectivity, written on the surface.
One subtle detail. Extracellular loop 1 (ECL1) of GIPR happens to contain three proline residues in a row. Prolines disrupt regular helical structure, so GIPR's ECL1 forms an unwound, relaxed loop rather than the small helix you see in GLP-1R's and GCGR's ECL1. The retatrutide C-terminus has to straighten out a little to accommodate that. Tiny differences like this — three prolines on one loop — are exactly the kind of structural feature designers exploit when they want to nudge a peptide's preference toward one receptor over another.
Same naming caveat as before. Retatrutide is an investigational compound. Research-grade retatrutide is a reference material for in-vitro and animal-model research. It is not the same product as any FDA-approved pharmaceutical.
How Researchers Actually Build These Peptides
Two complementary discovery routes dominate the literature.
The first is rational design from native hormone sequence. A researcher starts with GLP-1, GIP, or glucagon, identifies the residues responsible for receptor selectivity from prior structural work, and swaps specific positions to push affinity toward a second receptor while keeping activity at the first. Each candidate variant goes into a battery of cell-based assays measuring cAMP accumulation at each receptor in transfected cell lines, and the design iterates. A long-acting tail then gets attached to a lysine side chain via a fatty diacid linker — a C20 diacid on lysine 17 in retatrutide, on lysine 20 in tirzepatide — so the peptide binds albumin in serum and persists long enough to be useful in animal-model research (Zhao et al., 2022, PMC mirror).
The second route is combinatorial selection. Phage-displayed peptide libraries present billions of slightly different peptide variants on the surfaces of bacteriophages. By running alternating rounds of selection against each target receptor — first GCGR, then GLP-1R, then back — the experiment enriches for variants that bind both, without the researcher having to hand-design every position. Hits then move into the same cAMP-accumulation assays used in the rational-design route (Pearce et al., 2018). Combinatorial selection often surfaces unexpected backbones that rational design would never have proposed.
In practice, most working labs use both approaches in some combination: a phage-display library to find unusual starting points, rational sequence engineering to refine them, and structure-guided medicinal chemistry to lock in the half-life and the per-receptor potency ratio. None of this involves human administration; the entire pipeline up to clinical development is cell-culture and animal-model research.
The Second Design Axis — Biased Agonism
So far we've framed the design problem as one-dimensional: which receptors does the peptide engage, and how tightly? There's a second axis. Even after a peptide reaches and activates a receptor, the downstream signal it triggers can vary. The same receptor can route more of its signal through the cAMP pathway or through beta-arrestin recruitment, and can internalize faster or slower, depending on which residues on the extracellular surface the peptide contacts. The phenomenon is called biased agonism.
A 2016 paper on the GLP-1 receptor showed that the extracellular surface itself functions as a molecular trigger for biased signaling — different peptide agonists make different patterns of contact there, and those patterns map onto different downstream signaling profiles (Wootten et al., 2016). Closely related work has shown that GLP-1/GIP dual agonists confer a biased agonism that, on top of changing intracellular signaling, also modulates how the receptors get trafficked inside the cell (Willard et al., 2020).
For multi-receptor peptide designers, two things follow. First, two candidate peptides can have matched per-receptor binding profiles and still produce different observed responses in cell-based research, because they bias signaling differently. Second, biased signaling is itself a design output that can be tuned — by residue choice on the C-terminal half of the peptide — independently of which receptors the molecule engages. The design space is two-dimensional, not one.
Frequently Asked Questions
What is a multi-receptor agonist peptide?
It's a single peptide molecule rationally engineered so that one chemical sequence binds and activates two or more related receptors. The most-studied examples in research are the dual GIP/GLP-1 receptor agonist tirzepatide and the triple GLP-1/GIP/glucagon receptor agonist retatrutide — both single peptides that engage their target receptors at researcher-tunable potency ratios.
How can one peptide hit several different receptors?
The receptors involved — in the canonical case GLP-1R, GIPR, and GCGR — are close evolutionary cousins in the class B1 GPCR family. Their native hormones share enough sequence similarity that a single chimeric peptide can mimic features of two or three at once. The conserved transmembrane core of each receptor handles activation, while residues on the C-terminal half of the peptide tune which surface contacts are made and therefore which receptor it binds most tightly.
Is a triple agonist always better than a dual agonist?
Not automatically. In research models, adding glucagon-receptor activity to a GLP-1/GIP backbone can produce additional metabolic effects, but the glucagon component has to be tuned carefully — too much activity at GCGR shifts results in the wrong direction in cell-culture and animal studies. Multi-receptor design is a tuning exercise, not a "more is better" exercise.
Are multi-receptor peptides discovered or designed?
Both routes are used. The retatrutide and tirzepatide route is rational design from native hormone sequences and structure-guided medicinal chemistry. A second route uses phage-displayed peptide libraries to select variants that bind two receptors over alternating rounds of selection. Most labs use elements of both routes — combinatorial libraries surface unusual starting points, and rational design refines them.
Conclusion
One peptide can hit two or three receptors because the target receptors are close evolutionary cousins, the activation step is handled by a conserved transmembrane core, and the per-receptor selectivity sits on the extracellular surface where residue choice on the peptide's C-terminus determines which lock is preferred. The design space keeps expanding: combinatorial libraries surface new starting points, structure-guided redesign narrows the per-receptor potency ratios, and biased-signaling work has added a second axis to what was once treated as a one-dimensional binding question. For compound-specific reading, our pieces on tirzepatide and retatrutide work through each molecule in detail.
For research use only. Not for human or animal consumption of any kind. The information in this article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The statements made have not been evaluated by the U.S. Food and Drug Administration. These products are NOT FDA APPROVED. Please consult with a licensed healthcare professional before making any decisions regarding your health or research.
Optides LLC is a chemical supplier. Optides LLC is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Optides LLC is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.